MET and neuroblastoma: Of note, though the average cell death rate in non-neuroblastoma and non-ALK expressing cell lines (RD and VH7) was below 10% for all treatment conditions (Fig. 5f), crizotinib treatment increased the amount of dead cells, presumably by interacting with c-MET (Fig. 5a).